Literature DB >> 24649010

Interleukin-13 and its receptors in colorectal cancer (Review).

Ru Zhou1, Shiguang Qian2, Xiaodong Gu1, Zongyou Chen1, Jianbin Xiang1.   

Abstract

Interleukin (IL)-13 is an immunoregulatory cytokine secreted by numerous immune cells. Its functions are similar to those of IL-4 and they share a common receptor. This cytokine has been included in recent studies on human tumors and malignant diseases, evoking a scientific interest to investigate the role of IL-13 and its receptors as novel biomarkers and targets for therapy. Colorectal cancer is one of the most common human malignancies, its prognosis is not promising and the efficacy of molecular-targeted therapy has not been established. This review summarizes the currently available data on the role of IL-13 and its receptors in colorectal cancer, including the signaling pathways involved in mediating the effects of IL-13, the role of IL-13 and/or its receptors in the prediction of cancer and several drugs targeting IL-13 or its receptors that are currently under evaluation.

Entities:  

Keywords:  colorectal cancer; interleukin-13; interleukin-13 receptor

Year:  2013        PMID： 24649010      PMCID： PMC3916988          DOI： 10.3892/br.2013.132

Source DB:  PubMed          Journal:  Biomed Rep        ISSN： 2049-9434


  38 in total

Review 1.  Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.

Authors:  John J O'Shea; Massimo Gadina; Robert D Schreiber
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

2.  Association of -1112 c/t promoter region polymorphism of the interleukin 13 gene with occurrence of colorectal cancer.

Authors:  Anna Walczak; Karolina Przybyłowska; Radzisław Trzciński; Andrzej Sygut; Lukasz Dziki; Adam Dziki; Ireneusz Majsterek
Journal:  Pol Przegl Chir       Date:  2011-01

3.  Epithelial interleukin-4 receptor expression promotes colon tumor growth.

Authors:  Felicitas L Koller; Daniel G Hwang; E A Dozier; Barbara Fingleton
Journal:  Carcinogenesis       Date:  2010-02-22       Impact factor: 4.944

4.  Inflammation-related gene polymorphisms and colorectal adenoma.

Authors:  Marc J Gunter; Federico Canzian; Stefano Landi; Stephen J Chanock; Rashmi Sinha; Nathaniel Rothman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-06       Impact factor: 4.254

5.  The interleukin-13 receptor alpha2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway.

Authors:  K Kawakami; J Taguchi; T Murata; R K Puri
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

6.  Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains.

Authors:  J G Zhang; D J Hilton; T A Willson; C McFarlane; B A Roberts; R L Moritz; R J Simpson; W S Alexander; D Metcalf; N A Nicola
Journal:  J Biol Chem       Date:  1997-04-04       Impact factor: 5.157

Review 7.  IL-13 receptor-directed cancer vaccines and immunotherapy.

Authors:  Hideyuki Nakashima; Syed R Husain; Raj K Puri
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

8.  TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma.

Authors:  Yasuyuki Honjo; Yansong Bian; Koji Kawakami; Alfredo Molinolo; Glenn Longenecker; Ramanamurthy Boppana; Jonas Larsson; Stefan Karlsson; J Silvio Gutkind; Raj K Puri; Ashok B Kulkarni
Journal:  Cell Cycle       Date:  2007-06-05       Impact factor: 4.534

Review 9.  The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance.

Authors:  Warren Strober; Atsushi Kitani; Stefan Fichtner-Feigl; Ivan J Fuss
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

10.  Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response.

Authors:  Monica G Chiaramonte; Margaret Mentink-Kane; Bruce A Jacobson; Allen W Cheever; Matthew J Whitters; Mary E P Goad; Anthony Wong; Mary Collins; Debra D Donaldson; Michael J Grusby; Thomas A Wynn
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307
View more
  10 in total

1.  Deciphering the involvement of iron targets in colorectal cancer: a network biology approach.

Authors:  Abdul Arif Khan; Mohd Tashfeen Ashraf; Fahad M Aldakheel; Ayca Sayi Yazgan; Rana Zaidi
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.

Authors:  Giuseppe Ercolano; Alejandra Gomez-Cadena; Nina Dumauthioz; Giulia Vanoni; Mario Kreutzfeldt; Tania Wyss; Liliane Michalik; Romain Loyon; Angela Ianaro; Ping-Chih Ho; Christophe Borg; Manfred Kopf; Doron Merkler; Philippe Krebs; Pedro Romero; Sara Trabanelli; Camilla Jandus
Journal:  Nat Commun       Date:  2021-05-05       Impact factor: 14.919

3.  Single Nucleotide Polymorphisms in IL-10, IL-12p40, and IL-13 Genes and Susceptibility to Glioma.

Authors:  Haidar A Shamran; Haidar F Ghazi; Ahmed Al-Salman; Ahmad A Al-Juboory; Dennis D Taub; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh
Journal:  Int J Med Sci       Date:  2015-09-19       Impact factor: 3.738

4.  Can an IL13 -1112 C/T (rs1800925) polymorphism predict responsiveness to neoadjuvant chemoradiotherapy and survival of Chinese Han patients with locally advanced rectal cancer?

Authors:  Lin Xiao; Xin Yu; Rong Zhang; Hui Chang; Shaoyan Xi; Weiwei Xiao; Zhifan Zeng; Huizhong Zhang; Ruihua Xu; Yuanhong Gao
Journal:  Oncotarget       Date:  2016-06-07

5.  Interleukin-4 and interleukin-13 increase NADPH oxidase 1-related proliferation of human colon cancer cells.

Authors:  Han Liu; Smitha Antony; Krishnendu Roy; Agnes Juhasz; Yongzhong Wu; Jiamo Lu; Jennifer L Meitzler; Guojian Jiang; Eric Polley; James H Doroshow
Journal:  Oncotarget       Date:  2017-06-13

6.  Differential effects of peptidoglycan on colorectal tumors and intestinal tissue post-pelvic radiotherapy.

Authors:  Gen Li; Anqing Wu; Dandan Qi; Fengmei Cui; Yanan Zeng; Fang Xie; Hongya Wu; Yongping Gu; Qiu Chen; Xueguang Zhang
Journal:  Oncotarget       Date:  2016-11-15

Review 7.  Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.

Authors:  Francesca Romana Mariotti; Linda Quatrini; Enrico Munari; Paola Vacca; Lorenzo Moretta
Journal:  Front Immunol       Date:  2019-04-26       Impact factor: 7.561

8.  Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.

Authors:  Romain Loyon; Marine Jary; Bérengère Salomé; Alejandra Gomez-Cadena; Jeanne Galaine; Marie Kroemer; Pedro Romero; Sara Trabanelli; Olivier Adotévi; Christophe Borg; Camilla Jandus
Journal:  Front Immunol       Date:  2019-09-06       Impact factor: 7.561

9.  Macrophage depletion using clodronate liposomes decreases tumorigenesis and alters gut microbiota in the AOM/DSS mouse model of colon cancer.

Authors:  Jackie E Bader; Reilly T Enos; Kandy T Velázquez; Meredith S Carson; Mitzi Nagarkatti; Prakash S Nagarkatti; Ioulia Chatzistamou; J Mark Davis; James A Carson; Cory M Robinson; E Angela Murphy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-10-12       Impact factor: 4.871

10.  Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.

Authors:  Susan A Kennedy; Maria E Morrissey; Margaret R Dunne; Fiona O'Connell; Clare T Butler; Mary-Clare Cathcart; Amy M Buckley; Brian J Mehigan; John O Larkin; Paul McCormick; Breandán N Kennedy; Jacintha O'Sullivan
Journal:  BMC Cancer       Date:  2020-10-02       Impact factor: 4.430
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.